A significant proportion of the weight shed by individuals using popular obesity medications, such as Ozempic and Wegovy, may be attributed to muscle loss rather than solely fat reduction. Experts indicate that up to a third of the total weight lost could be lean muscle mass, raising concerns about the long-term health implications for patients.
This revelation has prompted the development of a new drug specifically designed to counteract this adverse effect. The aim is to allow patients to continue benefiting from the weight-loss properties of existing treatments while preserving crucial muscle tissue. Losing a substantial amount of muscle can have several negative consequences, including reduced strength, slower metabolism, and an increased risk of frailty, particularly in older adults.
Obesity medications, which work by mimicking a hormone that targets areas of the brain involved in appetite regulation, have proven highly effective in helping many individuals achieve significant weight reduction. However, the unexpected degree of muscle depletion has become a key focus for researchers. Maintaining muscle mass is vital for overall health, supporting bone density, physical mobility, and metabolic function.
The NHS currently offers some of these obesity jabs to eligible patients with a Body Mass Index (BMI) of 30 or above, or 27 and above with at least one weight-related comorbidity, such as type 2 diabetes. These treatments are typically part of a broader weight management programme that includes dietary advice and exercise. The potential for muscle loss underscores the importance of a holistic approach to weight management, emphasising protein intake and resistance training.
The development of a complementary drug to prevent muscle wastage could significantly improve the safety profile and long-term efficacy of current obesity treatments. It would allow patients to achieve healthier body compositions, where a greater proportion of weight loss comes from fat rather than muscle, thereby enhancing their overall health outcomes and quality of life.